On June 2021, CELLINK AB (“CELLINK”) entered into an agreement to acquire Discover Echo Inc. (“Discover Echo”), an innovative and revolutionary American company focusing on development, manufacturing, and sales of patented and unique hybrid microscopes that easily transform between Upright and Inverted configurations, merging the capabilities of multiple instruments into one.
Duff & Phelps, A Kroll Business, acted as the financial advisor to CELLINK and provided financial and tax due diligence in connection with the acquisition.
About CELLINK
Founded in 2016, CELLINK is a leading bioconvergence company that provides technologies, products, and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq Stockholm under CLNK B.
About Discover Echo
Discover Echo, founded in 2013 and headquartered in San Diego, is a fast-growing microscopy and imaging company with around 50 employees. The company serves customers mainly in North America, but has gained a strong presence in Europe and Asia and has a European subsidiary in the UK.
